A share price of Cabaletta Bio Inc [CABA] is currently trading at $2.74, up 12.76%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CABA shares have gain 32.05% over the last week, with a monthly amount glided 1.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cabaletta Bio Inc [NASDAQ: CABA] stock has seen the most recent analyst activity on December 20, 2024, when Evercore ISI downgraded its rating to a In-line and also revised its price target to $6 from $15. Previously, Wells Fargo downgraded its rating to Equal Weight on December 19, 2024, and dropped its price target to $6. On October 10, 2024, UBS initiated with a Buy rating and assigned a price target of $10 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $36 on February 05, 2024. William Blair initiated its recommendation with a Outperform and recommended $38 as its price target on November 29, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $40. In a note dated October 19, 2023, Stifel initiated an Buy rating and provided a target price of $31 on this stock.
Cabaletta Bio Inc experienced fluctuations in its stock price throughout the past year between $1.76 and $26.35. Currently, Wall Street analysts expect the stock to reach $16.33 within the next 12 months. Cabaletta Bio Inc [NASDAQ: CABA] shares were valued at $2.74 at the most recent close of the market. An investor can expect a potential return of 495.99% based on the average CABA price forecast.
Analyzing the CABA fundamentals
Gross Profit Margin for this corporation currently stands at 0.71% with Operating Profit Margin at -28.55%, Pretax Profit Margin comes in at -25.98%, and Net Profit Margin reading is -25.98%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.5 and Total Capital is -0.63. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.46 points at the first support level, and at 2.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.93, and for the 2nd resistance point, it is at 3.13.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cabaletta Bio Inc [NASDAQ:CABA] is 8.11. Also, the Quick Ratio is 8.11, while the Cash Ratio stands at 7.46.
